|
1
|
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance.
|
Arterioscler Thromb Vasc Biol
|
2008
|
5.44
|
|
2
|
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
|
N Engl J Med
|
2005
|
4.84
|
|
3
|
Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula.
|
J Mol Med (Berl)
|
2006
|
4.00
|
|
4
|
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
|
Circulation
|
2007
|
3.59
|
|
5
|
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
|
Circulation
|
2004
|
2.64
|
|
6
|
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein.
|
Circ Res
|
2006
|
2.50
|
|
7
|
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
|
Circulation
|
2012
|
2.25
|
|
8
|
Protective arms of the renin-angiotensin-system in neurological disease.
|
Clin Exp Pharmacol Physiol
|
2013
|
2.18
|
|
9
|
The endothelium and vascular inflammation in diabetes.
|
Diab Vasc Dis Res
|
2007
|
2.00
|
|
10
|
The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke.
|
J Hypertens
|
2008
|
1.91
|
|
11
|
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
|
J Hypertens
|
2008
|
1.81
|
|
12
|
Angiotensin AT1/AT2 receptors: regulation, signalling and function.
|
Blood Press
|
2003
|
1.79
|
|
13
|
Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein.
|
Arterioscler Thromb Vasc Biol
|
2004
|
1.75
|
|
14
|
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?
|
Circulation
|
2008
|
1.72
|
|
15
|
PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
|
Hypertension
|
2005
|
1.60
|
|
16
|
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
|
Diabetes
|
2005
|
1.58
|
|
17
|
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
|
Hypertension
|
2009
|
1.54
|
|
18
|
Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury.
|
FASEB J
|
2005
|
1.54
|
|
19
|
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB.
|
Hypertension
|
2010
|
1.50
|
|
20
|
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection.
|
Blood Press
|
2005
|
1.49
|
|
21
|
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled.
|
Am J Hypertens
|
2004
|
1.48
|
|
22
|
Angiotensin II and the fibroproliferative response to acute lung injury.
|
Am J Physiol Lung Cell Mol Physiol
|
2003
|
1.46
|
|
23
|
High prevalence and poor control of hypertension in primary care: cross-sectional study.
|
J Hypertens
|
2004
|
1.43
|
|
24
|
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.
|
J Hypertens
|
2014
|
1.40
|
|
25
|
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.
|
Diabetes
|
2007
|
1.39
|
|
26
|
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.
|
PLoS Genet
|
2008
|
1.35
|
|
27
|
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
|
Clin Res Cardiol
|
2008
|
1.34
|
|
28
|
Acidic pH and capsaicin activate mechanosensitive group IV muscle receptors in the rat.
|
Pain
|
2004
|
1.27
|
|
29
|
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
|
J Hypertens
|
2008
|
1.27
|
|
30
|
Excitatory and modulatory effects of inflammatory cytokines and neurotrophins on mechanosensitive group IV muscle afferents in the rat.
|
Pain
|
2005
|
1.19
|
|
31
|
Non-peptide AT2-receptor agonists.
|
Curr Opin Pharmacol
|
2010
|
1.15
|
|
32
|
Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance.
|
Stem Cells
|
2009
|
1.15
|
|
33
|
Novel therapeutic targets for hypertension.
|
Nat Rev Cardiol
|
2010
|
1.13
|
|
34
|
Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension.
|
Hypertension
|
2011
|
1.12
|
|
35
|
Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.
|
J Hypertens
|
2003
|
1.11
|
|
36
|
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
|
Cardiovasc Diabetol
|
2007
|
1.10
|
|
37
|
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
|
Lancet Neurol
|
2010
|
1.10
|
|
38
|
Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB.
|
FASEB J
|
2003
|
1.10
|
|
39
|
AT2 receptor agonists: hypertension and beyond.
|
Curr Opin Nephrol Hypertens
|
2012
|
1.09
|
|
40
|
Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury.
|
J Immunol
|
2010
|
1.08
|
|
41
|
Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
|
Hypertension
|
2012
|
1.07
|
|
42
|
Adenosine triphosphate as a stimulant for nociceptive and non-nociceptive muscle group IV receptors in the rat.
|
Neurosci Lett
|
2003
|
1.05
|
|
43
|
Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability.
|
Am J Physiol Heart Circ Physiol
|
2011
|
1.04
|
|
44
|
Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis.
|
Physiol Genomics
|
2004
|
1.02
|
|
45
|
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice.
|
Cardiovasc Diabetol
|
2010
|
1.02
|
|
46
|
Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
|
Diabetes
|
2008
|
1.01
|
|
47
|
The past, present and future of angiotensin II type 2 receptor stimulation.
|
J Renin Angiotensin Aldosterone Syst
|
2009
|
0.99
|
|
48
|
Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren.
|
J Hypertens
|
2008
|
0.99
|
|
49
|
Sensitization of rat dorsal horn neurons by NGF-induced subthreshold potentials and low-frequency activation. A study employing intracellular recordings in vivo.
|
Brain Res
|
2007
|
0.99
|
|
50
|
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
|
Brain Res
|
2008
|
0.98
|
|
51
|
Angiotensin receptor blockers and cerebral protection in stroke.
|
J Hypertens Suppl
|
2006
|
0.97
|
|
52
|
The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.
|
Fundam Clin Pharmacol
|
2009
|
0.96
|
|
53
|
Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats.
|
J Hypertens
|
2002
|
0.95
|
|
54
|
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.
|
Cardiovasc Drugs Ther
|
2002
|
0.94
|
|
55
|
Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart.
|
Hypertension
|
2013
|
0.94
|
|
56
|
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression.
|
Neurobiol Dis
|
2012
|
0.93
|
|
57
|
Cardiac inflammation after local irradiation is influenced by the kallikrein-kinin system.
|
Cancer Res
|
2012
|
0.93
|
|
58
|
Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components.
|
Atherosclerosis
|
2009
|
0.92
|
|
59
|
Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms.
|
Am J Cardiovasc Drugs
|
2005
|
0.91
|
|
60
|
Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.
|
J Hypertens
|
2008
|
0.91
|
|
61
|
Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation.
|
J Neurochem
|
2005
|
0.91
|
|
62
|
The angiotensin AT2 receptor in left ventricular hypertrophy.
|
J Hypertens
|
2010
|
0.90
|
|
63
|
Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells.
|
J Neurochem
|
2003
|
0.89
|
|
64
|
Impact of the AT(2) receptor agonist C21 on blood pressure and beyond.
|
Curr Hypertens Rep
|
2012
|
0.89
|
|
65
|
Aldosterone synthase inhibitors in cardiovascular and renal diseases.
|
Nephrol Dial Transplant
|
2014
|
0.89
|
|
66
|
Endothelial dysfunction and its role in diabetic vascular disease.
|
Endocrinol Metab Clin North Am
|
2006
|
0.89
|
|
67
|
Direct stimulation of angiotensin II type 2 receptor enhances spatial memory.
|
J Cereb Blood Flow Metab
|
2011
|
0.88
|
|
68
|
AT(2) receptor and tissue injury: therapeutic implications.
|
Curr Hypertens Rep
|
2014
|
0.87
|
|
69
|
Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage.
|
Hypertens Res
|
2009
|
0.87
|
|
70
|
Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites.
|
Hypertension
|
2005
|
0.87
|
|
71
|
The possible role of the NO-cGMP pathway in nociception: different spinal and supraspinal action of enzyme blockers on rat dorsal horn neurones.
|
Pain
|
2005
|
0.87
|
|
72
|
Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome.
|
J Mol Med (Berl)
|
2013
|
0.86
|
|
73
|
Cardiovascular protection for all individuals at high risk: evidence-based best practice.
|
Clin Res Cardiol
|
2008
|
0.86
|
|
74
|
Are angiotensin receptor blockers neuroprotective?
|
Curr Hypertens Rep
|
2004
|
0.86
|
|
75
|
New therapeutic pathways in the RAS.
|
J Renin Angiotensin Aldosterone Syst
|
2012
|
0.85
|
|
76
|
The angiotensin AT2 receptor in inflammation.
|
Drug News Perspect
|
2010
|
0.85
|
|
77
|
Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats.
|
Hum Mol Genet
|
2004
|
0.85
|
|
78
|
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.
|
Blood Press
|
2006
|
0.85
|
|
79
|
Estrogen receptor alpha supports cardiomyocytes indirectly through post-infarct cardiac c-kit+ cells.
|
J Mol Cell Cardiol
|
2009
|
0.85
|
|
80
|
Vasoactive peptides, their receptors and drug development.
|
Basic Clin Pharmacol Toxicol
|
2004
|
0.85
|
|
81
|
Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats.
|
J Hypertens
|
2005
|
0.85
|
|
82
|
The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling.
|
Biochem Pharmacol
|
2012
|
0.85
|
|
83
|
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
|
Am Heart J
|
2013
|
0.84
|
|
84
|
Adapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology.
|
J Renin Angiotensin Aldosterone Syst
|
2009
|
0.84
|
|
85
|
Key advances in antihypertensive treatment.
|
Nat Rev Cardiol
|
2012
|
0.84
|
|
86
|
Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.
|
Expert Rev Cardiovasc Ther
|
2006
|
0.83
|
|
87
|
Cardiac PPARalpha expression in patients with dilated cardiomyopathy.
|
Eur J Heart Fail
|
2005
|
0.83
|
|
88
|
HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients.
|
Blood Press
|
2004
|
0.83
|
|
89
|
p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells.
|
Biochem Biophys Res Commun
|
2003
|
0.83
|
|
90
|
How do disorder, reorganization, and localization influence the hole mobility in conjugated copolymers?
|
J Am Chem Soc
|
2013
|
0.82
|
|
91
|
Emerging drugs which target the renin-angiotensin-aldosterone system.
|
Expert Opin Emerg Drugs
|
2011
|
0.82
|
|
92
|
Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP) genes.
|
Biochem Pharmacol
|
2009
|
0.82
|
|
93
|
Pathophysiological activity in rat dorsal horn neurones in segments rostral to a chronic spinal cord injury.
|
Brain Res
|
2003
|
0.82
|
|
94
|
Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes.
|
PLoS One
|
2010
|
0.82
|
|
95
|
Inhibiting angiotensin type 1 receptors as a target for diabetes.
|
Expert Opin Ther Targets
|
2008
|
0.82
|
|
96
|
ANG III induces expression of inducible transcription factors of AP-1 and Krox families in rat brain.
|
Am J Physiol Regul Integr Comp Physiol
|
2005
|
0.81
|
|
97
|
The promyelocytic leukemia zinc finger (PLZF) protein exerts neuroprotective effects in neuronal cells and is dysregulated in experimental stroke.
|
Brain Pathol
|
2011
|
0.81
|
|
98
|
The metabolic syndrome: cluster with a self-fulfilling loop?
|
J Hypertens
|
2006
|
0.81
|
|
99
|
Activity profile of calpains I and II in chronically infarcted rat myocardium--influence of the calpain inhibitor CAL 9961.
|
Br J Pharmacol
|
2002
|
0.81
|
|
100
|
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
|
Int Immunopharmacol
|
2003
|
0.81
|
|
101
|
Perspective: A tale of two receptors.
|
Nature
|
2013
|
0.80
|
|
102
|
Effects of endothelin ETA receptor blocker LU 135252 on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure.
|
Acta Pharmacol Sin
|
2006
|
0.80
|
|
103
|
High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.
|
Hypertension
|
2011
|
0.80
|
|
104
|
Stimulation of the Angiotensin II AT2 Receptor is Anti-inflammatory in Human Lipopolysaccharide-Activated Monocytic Cells.
|
Inflammation
|
2015
|
0.80
|
|
105
|
Bradykinin B1 and B2 receptors differentially regulate cardiac Na+-H+ exchanger, Na+-Ca2+ exchanger and Na+-HCO3- symporter.
|
Eur J Pharmacol
|
2003
|
0.79
|
|
106
|
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.
|
PLoS One
|
2011
|
0.79
|
|
107
|
Angiotensin II type 2 receptor agonists--where should they be applied?
|
Expert Opin Investig Drugs
|
2012
|
0.79
|
|
108
|
PLZF and the (pro)renin receptor.
|
J Mol Med (Berl)
|
2008
|
0.79
|
|
109
|
Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
|
J Renin Angiotensin Aldosterone Syst
|
2003
|
0.79
|
|
110
|
Mast cell-derived TNF-α and histamine modify IL-6 and IL-8 expression and release from cutaneous tumor cells.
|
Exp Dermatol
|
2011
|
0.78
|
|
111
|
Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats.
|
Int J Biochem Cell Biol
|
2003
|
0.78
|
|
112
|
AT2 receptors targeting cardiac protection post-myocardial infarction.
|
Curr Hypertens Rep
|
2014
|
0.78
|
|
113
|
Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro.
|
Cardiovasc Res
|
2003
|
0.78
|
|
114
|
Identification of a zinc finger homoeodomain enhancer protein after AT(2) receptor stimulation by differential mRNA display.
|
Arterioscler Thromb Vasc Biol
|
2002
|
0.77
|
|
115
|
Ethanol-induced downregulation of the angiotensin AT2 receptor in murine fibroblasts is mediated by PARP-1.
|
Alcohol
|
2010
|
0.77
|
|
116
|
High-mobility group A1 protein: a new coregulator of peroxisome proliferator-activated receptor-γ-mediated transrepression in the vasculature.
|
Circ Res
|
2011
|
0.77
|
|
117
|
Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode.
|
Bioorg Med Chem
|
2010
|
0.77
|
|
118
|
Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival.
|
Neurol Res
|
2011
|
0.77
|
|
119
|
Distinct signal transduction pathways downstream of the (P)RR revealed by microarray and ChIP-chip analyses.
|
PLoS One
|
2013
|
0.77
|
|
120
|
Regulation of tyrosine phosphatases in the adventitia during vascular remodelling.
|
Biochem Biophys Res Commun
|
2009
|
0.77
|
|
121
|
Rats with chronic spinal cord transection as a possible model for the at-level pain of paraplegic patients.
|
Neurosci Lett
|
2002
|
0.76
|
|
122
|
The pharmacological rationale behind polypharmacy in heart failure.
|
Heart Fail Monit
|
2008
|
0.76
|
|
123
|
Calcium channel blockade limits transcriptional, translational and functional up-regulation of the cardiac calpain system after myocardial infarction.
|
Eur J Pharmacol
|
2002
|
0.76
|
|
124
|
Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease?
|
CNS Drugs
|
2002
|
0.76
|
|
125
|
Mast cells and the power of local RAS activation.
|
Nephrol Dial Transplant
|
2006
|
0.76
|
|
126
|
Characterization of new PPARgamma agonists: analysis of telmisartan's structural components.
|
ChemMedChem
|
2009
|
0.76
|
|
127
|
Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension.
|
Diabetes Res Clin Pract
|
2010
|
0.76
|
|
128
|
A polymorphic microsatellite repeat within the ECE-1c promoter is involved in transcriptional start site determination, human evolution, and Alzheimer's disease.
|
J Neurosci
|
2012
|
0.76
|
|
129
|
Acute stress and long-lasting blood pressure elevation: a possible cause of established hypertension?
|
J Hypertens
|
2005
|
0.75
|
|
130
|
Angiotensin receptors and autophagy: live and let die.
|
Hypertension
|
2009
|
0.75
|
|
131
|
Does the AT2-receptor mediate anti-atherosclerotic actions?
|
J Hypertens
|
2005
|
0.75
|
|
132
|
Angiotensin II receptor expression: from maturation to pathogenesis.
|
Am J Physiol Regul Integr Comp Physiol
|
2003
|
0.75
|
|
133
|
The angiotensin type 2 receptor and the kidney.
|
Curr Opin Nephrol Hypertens
|
2017
|
0.75
|
|
134
|
Risk factors: Plasma renin activity predicts renal impairment.
|
Nat Rev Nephrol
|
2012
|
0.75
|
|
135
|
Comment on "protective arms of the renin-angiotensin system in neurological disease": Reply.
|
Clin Exp Pharmacol Physiol
|
2013
|
0.75
|
|
136
|
[Cooperation between university-industry].
|
Med Klin (Munich)
|
2004
|
0.75
|
|
137
|
Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
|
Am J Hypertens
|
2003
|
0.75
|
|
138
|
Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.
|
Acta Pharmacol Sin
|
2004
|
0.75
|
|
139
|
Angiotensin in the kidney: a key to understanding hypertension?
|
Cell Metab
|
2007
|
0.75
|
|
140
|
Prevention of coronary artery disease: recent advances in the management of hypertension.
|
Curr Atheroscler Rep
|
2013
|
0.75
|
|
141
|
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
|
Expert Opin Pharmacother
|
2004
|
0.75
|
|
142
|
[Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure].
|
Drugs
|
2002
|
0.75
|
|
143
|
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
|
J Hypertens Suppl
|
2009
|
0.75
|
|
144
|
Moderate correlations of in vitro versus in vivo pharmacokinetics questioning the need of early microsomal stability testing.
|
Pharmacology
|
2012
|
0.75
|
|
145
|
Plasma renin and cardiovascular risk: what is the evidence for an association?
|
Cardiology
|
2013
|
0.75
|
|
146
|
Pharmacoeconomics and quality of life analysis of telmisartan in hypertension treatment.
|
Expert Rev Pharmacoecon Outcomes Res
|
2007
|
0.75
|
|
147
|
An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.
|
Expert Rev Cardiovasc Ther
|
2013
|
0.75
|
|
148
|
Advances in cardiovascular research. 15th Annual Meeting of the European Council for Cardiovascular Research (ECCR). La Colle sur Loup, France, 8–10 October 2010.
|
Expert Rev Cardiovasc Ther
|
2011
|
0.75
|
|
149
|
Cleaved high molecular weight kininogen, a novel factor in the regulation of matrix metalloproteinases in vascular smooth muscle cells.
|
Biochem Pharmacol
|
2009
|
0.75
|
|
150
|
Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2.
|
ChemMedChem
|
2009
|
0.75
|
|
151
|
Inflammation in the genesis of hypertension and its complications--the role of angiotensin II.
|
Nephrol Dial Transplant
|
2007
|
0.75
|
|
152
|
Tissue-Specific Expression of a Rat Renin Transcript Lacking the Coding Sequence for the Prefragment and Its Stimulation by Myocardial Infarction.
|
Endocrinology
|
2000
|
0.75
|
|
153
|
The cardiovascular continuum refined: A hypothesis.
|
Blood Press
|
2010
|
0.75
|
|
154
|
Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.
|
Eur J Prev Cardiol
|
2013
|
0.75
|
|
155
|
Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension.
|
Curr Med Res Opin
|
2010
|
0.75
|